NASDAQ:TNFA TNF Pharmaceuticals (TNFA) Stock Price, News & Analysis $3.89 -0.10 (-2.51%) As of 06/23/2026 Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesSEC FilingsTrendsBuy This Stock About TNF Pharmaceuticals Stock (NASDAQ:TNFA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get TNF Pharmaceuticals alerts:Sign Up Key Stats Today's Range$3.85▼$4.1450-Day Range$3.61▼$5.1352-Week Range$0.04▼$8.94Volume250,052 shsAverage Volume32.22 million shsMarket Capitalization$7.18 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview TNF Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company. It focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. The MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases. The company's second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy. The Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve the growing CBD market, which includes FDA approved drugs and CBD products not regulated as drugs. TNF Pharmaceuticals, Inc. was formerly known as MyMD Pharmaceuticals, Inc. and changed its name to TNF Pharmaceuticals, Inc. in July 2024. The company was founded in 2014 and is headquartered in Baltimore, Maryland. Read More TNF Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks5th Percentile Overall ScoreTNFA MarketRank™: TNF Pharmaceuticals scored higher than 5% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.5 / 5Analyst RatingSell Consensus RatingTNF Pharmaceuticals has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageTNF Pharmaceuticals has received no research coverage in the past 90 days.Read more about TNF Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of TNF Pharmaceuticals is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of TNF Pharmaceuticals is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTNF Pharmaceuticals has a P/B Ratio of 0.01. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for TNFA. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTNF Pharmaceuticals does not currently pay a dividend.Dividend GrowthTNF Pharmaceuticals does not have a long track record of dividend growth. News and Social Media3.1 / 5News SentimentN/A News SentimentTNF Pharmaceuticals has a news sentiment score of 0.95. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.63 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for TNF Pharmaceuticals this week, compared to 0 articles on an average week. Company Ownership0.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, TNF Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders0.45% of the stock of TNF Pharmaceuticals is held by insiders.Percentage Held by Institutions9.64% of the stock of TNF Pharmaceuticals is held by institutions.Read more about TNF Pharmaceuticals' insider trading history. Receive TNFA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for TNF Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TNFA Stock News HeadlinesTNF Pharmaceuticals (Formerly MyMD Pharmaceuticals) Begins Trading Under New Nasdaq Stock Symbol “TNFA” Effective Before Market Open TodayJune 23 at 2:38 PM | businesswire.comWhy did QCLS stock surge over 60% today?December 4, 2025 | msn.comYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. They don't know the rules. They don't know what to avoid. And they hand their account to Wall Street on a silver platter. Normally $29.97. Free today.June 24 at 1:00 AM | Profits Run (Ad)Rheumatoid Arthritis Market to Surge by 2034 as Next-Generation Biologics and JAK Inhibitors Gain Traction | DelveInsightNovember 5, 2025 | finance.yahoo.comForward Therapeutics Announces First Participants Dosed in Phase 1 Healthy Volunteer Study of FT2109, a Next-Generation TNF Signaling InhibitorOctober 30, 2025 | markets.businessinsider.comQ/C Technologies (Formerly TNF Pharmaceuticals) Commences Trading on Nasdaq Under New Ticker Symbol "QCLS"September 26, 2025 | tmcnet.comTNF Pharmaceuticals changes name to Q/C TechnologiesSeptember 25, 2025 | msn.comTNF Pharmaceuticals stock soars after strategic pivot to quantum computingSeptember 25, 2025 | investing.comSee More Headlines TNFA Stock Analysis - Frequently Asked Questions How have TNFA shares performed this year? TNF Pharmaceuticals' stock was trading at $3.99 at the beginning of the year. Since then, TNFA shares have decreased by 2.5% and is now trading at $3.89. How were TNF Pharmaceuticals' earnings last quarter? TNF Pharmaceuticals, Inc. (NASDAQ:TNFA) released its quarterly earnings results on Tuesday, August, 19th. The company reported ($18.00) earnings per share (EPS) for the quarter. When did TNF Pharmaceuticals' stock split? TNF Pharmaceuticals shares reverse split on the morning of Tuesday, September 2nd 2025.The 1-100 reverse split was announced on Thursday, August 28th 2025. The number of shares owned by shareholders was adjusted after the market closes on Friday, August 29th 2025. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. How do I buy shares of TNF Pharmaceuticals? Shares of TNFA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of TNF Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that TNF Pharmaceuticals investors own include Amprius Technologies (AMPX), Archrock (AROC), Axon Enterprise (AXON), PACCAR (PCAR), Bitfarms (BITF), Bitfarms (BFARF) and BigBear.ai (BBAI). Company Calendar Last Earnings8/19/2025Today6/24/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:TNFA Previous SymbolNASDAQ:MYMD CIK1321834 Webtnfpharma.com Phone(856) 848-8698Fax856-848-0269Employees6Year FoundedN/AProfitability EPS (Trailing Twelve Months)($231.00) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$23.36 million Net MarginsN/A Pretax MarginN/A Return on Equity-69.21% Return on Assets-33.98% Debt Debt-to-Equity RatioN/A Current Ratio0.93 Quick Ratio0.93 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$286.76 per share Price / Book0.01Miscellaneous Outstanding Shares1,847,000Free Float1,839,000Market Cap$7.18 million OptionableN/A Beta2.04 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:TNFA) was last updated on 6/24/2026 by MarketBeat.com Staff. From Our PartnersFirm That Predicted 2008, 2020, 2022: Right Now Looks WorseThe firm that predicted the dot-com crash, the 2008 financial crisis, the 2020 COVID crash, and the 2022 bear ...TradeSmith | SponsoredThe Treasury just bought its own debtOn April 16th, the U.S. Treasury executed a $15 billion buyback of its own debt - the largest in history - whi...Golden Portfolio | SponsoredElon’s message for AmericaElon Musk bought Super Bowl ad time at $266,000 per second - something he has never done before. 125 million A...Stansberry Research | SponsoredBlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely, LLC | SponsoredElon Is Quietly Doubling Down on This Bizarre AssetYahoo Finance reports this technology 'May Unlock $400 Trillion' - and Bloomberg calls it 'unavoidable.' Elon ...Brownstone Research | Sponsored“The unseen winner of the AI race” is not SpaceXMarc Chaikin - the analyst who called Nvidia before its historic run - says a tech firm labeled 'the unseen wi...Chaikin Analytics | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredPH: Do THESE 4 things to your bank account now …In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TNF Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TNF Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
